Inotrem Receives Funding From the Crohn’s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)
Summary
PARIS--(BUSINESS WIRE)--Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohns & Colitis Foundations IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. Lasting over 18 months, the project will be a cornerstone in the design of Inotrems first-in-human clinical study with INO-02.There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases, indicates Sven Zimmermann, CEO of Inotrem.Beyond the financial support, this is a strong recognition of Inotrems scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target, says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. www.inotrem.comThe Crohns & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohns disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD.